Disclosure: We may earn a commission if you sign up through some links on this site, at no extra cost to you. We do not accept payment for favorable reviews. Read our full affiliate disclosure.
Ivím Health at a Glance
- What it is
- The most generous clinical access here — and an FDA warning letter in February 2026 that it appears to have taken seriously
- Medication type
- Compounded only
- Medications offered
- Compounded semaglutide
- Compounded tirzepatide
- Compounded liraglutide, reported from $249/month
- Pricing
- $75/mo membership (first month free) plus prepaid medication — about $181/mo all-in on the 4-month semaglutide plan
- Insurance
- Not applicable. Compounded medication is cash-pay everywhere, and Ivím is a cash-pay service.
- Date reviewed
- August 7, 2026
How we scored it
Scores follow the published rubric in our provider comparison methodology.
Medical Disclaimer
We're not doctors, and this review is not medical advice. GLP-1 medications are prescription-only and require evaluation by a licensed healthcare provider. What works for one person may not work for another, and only a clinician who knows your history can determine whether a medication is appropriate for you. See our full medical disclaimer.
What Is Ivím Health?
Ivím leads on clinical access rather than the lowest medication price, and on that measure it is the strongest service in this comparison. The $75/month membership — first month free — buys unlimited video visits with licensed providers, 1-on-1 health coaching sessions, 24/7 clinical team support by text or call, private community access, progress tracking, an education library, a 20% supplement discount and access to hormone therapy programmes. Nobody else here bundles that much contact.
The membership is mandatory and tied to your medication plan length, which Ivím states plainly rather than burying. Medication is then sold as a prepaid block: compounded semaglutide at $379 for two months or $499 for four, and compounded tirzepatide at $550 for two months or $900 for four, each described as the total due today and including the first month of membership.
Do the arithmetic the site does not do for you, because "total due today" is not your total cost. On the four-month semaglutide plan you pay $499 up front and then three further months of membership at $75, which is $724 across four months, or about $181/month all-in. Four-month tirzepatide is $900 plus $225, so roughly $281/month. The two-month plans work out worse — around $227/month for semaglutide and $313/month for tirzepatide — because the membership is amortised over fewer months.
The material fact that was not in our previous review: on 20 February 2026 the FDA issued Ivim Services LLC a warning letter, one of a batch of 29 sent by CDER that day. Having reviewed the website in December 2025, the agency concluded that the compounded semaglutide and tirzepatide products offered there were misbranded under sections 502(a) and 502(bb) of the FD&C Act and introduced into interstate commerce in violation of section 301(a). The objection was to how the products were represented on the site. The FDA did not allege sterility problems or contamination.
What we can see today is a pricing page carrying the statement that "Compounded drugs are permitted to be prescribed under federal law but are not FDA-approved and do not undergo safety, effectiveness, or manufacturing review" — which is a more complete disclosure than most of its competitors make, and reads like a company that responded to the letter. That does not erase the letter; it does tell you something about what happened next.
How the Program Works
- Consultation process
- A free consultation, then a visit with an Ivím provider. Unlimited video visits with licensed providers are included in the membership thereafter, with 24/7 clinical team support by text or call.
- Eligibility
- Clinician-assessed. Ivím frames its offering around metabolic health more broadly than weight alone, and also runs hormone therapy programmes.
- Provider involvement
- A large licensed provider network with unlimited visits and same-day availability advertised, plus 1-on-1 health coaching sessions as a separate included service. This is the strongest clinician-contact offer in this comparison.
- Lab requirements
- Determined clinically rather than set as a fixed protocol, and not published as a universal requirement or a published cost.
- Pharmacy fulfillment
- Compounded medication from partner compounding pharmacies. Ivím does not publicly name an exclusive pharmacy or state 503A versus 503B.
- Shipping frequency
- Aligned to the prepaid plan you buy — two or four months.
- Support services
- Unlimited video visits, 1-on-1 health coaching, 24/7 clinical team support by text or call, private community access, progress tracking tools, an educational content library, a 20% supplement discount, and access to hormone therapy programmes.
Ivím Health Pricing
- Membership fee
- $75/month, first month free, required for the duration of the medication plan you select. Ivím states the requirement openly.
- Medication fee
- Compounded semaglutide: $379 for two months or $499 for four, quoted as total due today and including the first month of membership. Compounded tirzepatide: $550 for two months or $900 for four, on the same basis. Compounded liraglutide is reported from $249/month.
- Cancellation policy
- The membership runs for the duration of the medication plan you select, and the medication is prepaid. Ivím does not publish what happens to an unused balance if you stop mid-plan — ask before committing to a four-month block.
- Refund policy
- Not published. With $499 to $900 payable up front, this is the question to get answered in writing first.
- Insurance
- Not applicable. Compounded medication is cash-pay everywhere, and Ivím is a cash-pay service.
- HSA / FSA
- Membership and medication costs are commonly HSA/FSA-eligible as medical expenses. Confirm with your administrator; compounded medication reimbursement is not guaranteed.
Pricing details worth knowing
- The advertised figure is "total due today", not your total. Add $75/month membership for every month of the plan after the first.
- All-in, the four-month semaglutide plan is about $724 across four months — roughly $181/month.
- All-in, the four-month tirzepatide plan is about $1,125 across four months — roughly $281/month.
- The two-month plans are worse value per month because the membership is spread over fewer months.
- You are paying a premium for clinical access. If you want the lowest medication price and expect to need little contact, this is not the cheapest route.
Prices change. Every figure above was taken from Ivím Health's published pages or the named sources at the bottom of this review, as of August 7, 2026. Telehealth pricing in this market changes frequently, and promotional rates expire. Confirm your actual cost at checkout before enrolling.
Pros and Cons
Pros
- The most clinical contact of any provider here — unlimited video visits, 1-on-1 coaching and 24/7 support in one membership
- First month of membership free
- States the membership requirement plainly rather than burying it
- Publishes an unusually complete compounding disclosure: compounded drugs "are not FDA-approved and do not undergo safety, effectiveness, or manufacturing review"
- Prices are published on the site rather than gated behind an intake
- Hormone therapy and a supplement discount included in the same membership
Cons
- Received an FDA warning letter on 20 February 2026 over misbranded compounded semaglutide and tirzepatide
- The advertised price is "total due today" and excludes the ongoing membership — real cost is materially higher
- Mandatory membership tied to your medication plan length
- Medication is prepaid in two- or four-month blocks with no published refund policy
- Compounded only — no brand-name pathway
- Does not name its compounding pharmacy or publish lab requirements
Who Ivím Health May Be Best For
People who expect to need frequent clinician contact during titration, which is when most people struggle
Anyone who has had trouble getting appointments or responses elsewhere
Patients who want coaching and hormone therapy on the same account
Limitations
Read the FDA letter for what it is. It concerned how products were represented on the website, not sterility or contamination, and Ivím's current disclosure is better than most. But it is a fact about the company that belongs in your decision, and we did not have it in our earlier review.
Calculate the all-in monthly figure before enrolling, not the "total due today". The membership continues after the first month and is required for the whole plan.
Get the refund position in writing before prepaying $499 to $900.
Ask which pharmacy compounds your medication and whether it is 503A or 503B.
If you want brand-name medication, Ivím has no pathway to it — NovoCare and LillyDirect sell direct for less than most resellers charge.
About Compounded GLP-1s
The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, which ended the window for compounding pharmacies to make large volumes of copies of those drugs (503A pharmacies had until April 22, 2025; 503B outsourcing facilities until May 22, 2025). Many telehealth companies continue to offer compounded GLP-1s prescribed for an individual patient — often as a personalized dose, a microdose, or a formulation combined with a vitamin such as B12 or B6. That practice sits in a contested legal area, and the FDA has continued to act. In a Federal Register notice published on May 1, 2026, the FDA proposed not to include semaglutide, tirzepatide or liraglutide on the 503B bulks list, saying it had not identified sufficient evidence of a clinical need for outsourcing facilities to compound them from bulk substances; the comment period was extended to July 30, 2026. Separately, in February 2026 the FDA issued warning letters to 30 telehealth companies over false or misleading claims about compounded GLP-1s, and it has continued: a further round dated 8 June 2026 — 25 warning letters, posted publicly on 16 June 2026 — reached companies including Medica Weight Loss, FITISH and Roen Health (RoenRx), again over false or misleading claims about compounded semaglutide and tirzepatide that the FDA said made the products misbranded under sections 502(a) and 502(bb) of the FD&C Act. The claims cited included suggesting the products were FDA-approved, implying equivalence to Ozempic, Wegovy, Mounjaro or Zepbound, and asserting the "same active ingredient" or "same results" as the approved drugs. Compounded medications are not FDA-approved, which means they have not gone through the same review as the brand-name products.
None of that is specific to Ivím Health — it applies to every provider offering compounded medication. We cover the trade-offs in detail in our guide to brand-name versus compounded GLP-1s.
Alternatives to Ivím Health
Mochi Health
Similar membership-plus-medication structure with flat medication pricing at every dose
Read review →NovoCare Pharmacy
FDA-approved Wegovy direct at $149–$199/mo with no membership and no compounding questions
Read review →TrimRx
A single medication price with no separate membership to add on
Read review →vs. CoreAge RX, our top-rated platform
Across the platforms we've reviewed, CoreAge RX remains our highest-rated option for cash-pay patients, with compounded semaglutide from $99/month and tirzepatide from $149/month including free two-day shipping. Whether it beats Ivím Health for you depends on the things this review has covered — insurance, medication type, and how much support you actually want.
Frequently Asked Questions
Did Ivím Health receive an FDA warning letter?
Yes. On 20 February 2026 the FDA issued a warning letter to Ivim Services LLC, one of a batch of 29 sent by its drug centre that day. After reviewing the website in December 2025, the agency concluded the compounded semaglutide and tirzepatide products offered there were misbranded under sections 502(a) and 502(bb) of the FD&C Act and introduced into interstate commerce in violation of section 301(a). Two things are worth knowing about it: the objection was to website representations rather than to product safety — the FDA did not allege sterility issues or contamination — and Ivím's pricing page now carries a fuller compounding disclosure than most of its competitors do.
How much does Ivím Health actually cost per month?
More than the advertised number, because the headline figures are "total due today" and exclude the ongoing membership. The four-month compounded semaglutide plan is $499 up front plus three further months of membership at $75, so about $724 across four months — roughly $181/month. Four-month tirzepatide is $900 plus $225, about $281/month. The two-month plans are worse per month: roughly $227 for semaglutide and $313 for tirzepatide, because the membership is spread across fewer months.
Is the Ivím membership required?
Yes, and Ivím says so openly, which is to its credit. The membership is $75/month with the first month free, and it is required for the duration of the medication plan you select. What it buys is unlimited video visits with licensed providers, 1-on-1 health coaching, 24/7 clinical team support by text or call, community access, progress tracking, an education library, a 20% supplement discount and access to hormone therapy programmes.
Is Ivím worth the membership fee?
It depends entirely on how much contact you want. If you expect to need frequent clinician access — and titration is when most people do — this is the most generous access offer in this comparison and the fee is buying something real. If you know what you are doing, expect to message someone twice a year and simply want the lowest price, you are paying $75 a month for capacity you will not use, and providers with no membership fee will cost you less.
Who should not use Ivím Health?
Anyone who wants brand-name FDA-approved medication, since there is no pathway to it here. Anyone unwilling to prepay two to four months without a published refund policy. Anyone who wants the lowest possible price and will not use the clinical access. Separately, GLP-1 medications are not appropriate if you have a personal or family history of medullary thyroid carcinoma or MEN 2, if you are pregnant or trying to conceive, or if you have had pancreatitis.
The Verdict
Ivím sells compounded semaglutide and tirzepatide as prepaid 2- or 4-month plans on top of a required $75/month membership that buys unlimited video visits, 1-on-1 coaching and 24/7 clinical support. It received an FDA warning letter on 20 February 2026 over misbranding — about website claims, not product safety — and its pricing page now carries one of the clearest compounding disclosures we have seen.
Opens Ivím Health's official site · Verify current pricing there
Compare Every Provider Side by Side
See how Ivím Health stacks up against every platform we've reviewed on price, medication type, and what's actually included.
How We Researched This Review
We compiled this review on August 7, 2026 from Ivím Health's own published pages plus independent reporting. We have not signed up for this service ourselves, and we say so rather than implying firsthand testing. Where Ivím Health does not publish a detail — refund terms, lab requirements, pharmacy partners — we've said that plainly instead of guessing.
Sources
- ivimhealth.com/glp1-pricing — compounded semaglutide $379 (2-month) and $499 (4-month) total due today; compounded tirzepatide $550 (2-month) and $900 (4-month); "Prices include compounded medication and your first month of Ivím Membership ($75/mo required thereafter)"; membership inclusions listed as unlimited video visits, 1-on-1 health coaching, private community access, 24/7 clinical team support via text/call, progress tracking tools, educational content library, 20% supplement discount and access to hormone therapy programs; disclosure that "Compounded drugs are permitted to be prescribed under federal law but are not FDA-approved and do not undergo safety, effectiveness, or manufacturing review" (checked August 7, 2026)
- FDA warning letter, Ivim Services LLC dba Ivim, reference 721816, dated 20 February 2026 — compounded semaglutide and tirzepatide products found misbranded under FD&C Act sections 502(a) and 502(bb) and introduced into interstate commerce in violation of section 301(a), following FDA review of the website in December 2025; issued as part of a batch of 29 warning letters from CDER that day
- Third-party reviewers reporting Ivím medication pricing by plan length, including compounded liraglutide from $249/month (not verified against Ivím's own pages)
Affiliate Disclosure: This review may contain affiliate links. If you click a link and sign up, we may receive a commission at no additional cost to you. We do not accept payment for favorable coverage, and commission relationships do not affect our scores. Read our full affiliate disclosure policy.